V
VERONA PHARMA PLC ADR
NASDAQ: VRNA (Verona Pharma plc)
Last update: 12 hours ago106.61
-0.08 (-0.07%)
| Previous Close | 106.69 |
| Open | 106.75 |
| Volume | 1,140,173 |
| Avg. Volume (3M) | 3,544,415 |
| Market Cap | 9,059,598,336 |
| Price / Earnings (Forward) | 35.34 |
| Price / Sales | 40.36 |
| Price / Book | 33.01 |
| 52 Weeks Range | |
| Earnings Date | 3 Nov 2025 |
| Profit Margin | -138.31% |
| Operating Margin (TTM) | -13.53% |
| Diluted EPS (TTM) | -2.00 |
| Total Debt/Equity (MRQ) | 107.63% |
| Current Ratio (MRQ) | 8.86 |
| Operating Cash Flow (TTM) | -120.15 M |
| Levered Free Cash Flow (TTM) | -69.15 M |
| Return on Assets (TTM) | -20.64% |
| Return on Equity (TTM) | -72.61% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Verona Pharma plc | Bearish | Bullish |
AIStockmoo Score
-1.8
| Analyst Consensus | -3.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | -5.0 |
| Technical Oscillators | 2.0 |
| Average | -1.75 |
|
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 10.57% |
| % Held by Institutions | 91.12% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Summit Partners Public Asset Management, Llc | 30 Jun 2025 | 2,144,286 |
| 52 Weeks Range | ||
| Median | 100.00 (-6.20%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Cantor Fitzgerald | 08 Oct 2025 | 100.00 (-6.20%) | Buy | 106.91 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |